Catalyst Repository | Stealth BioTherapeutics Corp. ADS

Stealth BioTherapeutics Corp. ADS

(NASDAQ:MITO)

Description

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases. The company's product candidates include SBT-20, a small peptide that targets and binds reversibly to cardiolipin, stabilizing mitochondrial structure, and function under conditions of oxidative stress; and SBT-272, a lead discovery pipeline compound, evaluating for rare neurodegenerative diseases, such as amyotrophic lateral sclerosis. Stealth BioTherapeutics Corp was founded in 2006 and is based in George Town, the Cayman Islands.

MITO Overview

None
Sector
Health Care
Industry
Major Pharmaceuticals

Previous Close
$0.2400
Previous Close Volume
838070